Rangering i aksjer
#12737
Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to... Graphite Bio, Inc. is a clinical-stage gene editing company dedicated to developing innovative therapeutic solutions for severe and life-threatening illnesses across the United States. Its primary investigational therapy, GPH101, is an autologous, gene-edited hematopoietic stem cell product specifically engineered to directly correct the underlying mutation causing sickle cell disease, thereby restoring normal adult hemoglobin production. The company's pipeline also features GPH201, intended for the treatment of X-linked severe combined immunodeficiency syndrome, and GPH301, an experimental candidate designed to address Gaucher disease, a genetic disorder characterized by a deficiency in the glucocerebrosidase enzyme. Initially established as Integral Medicines, Inc., the company rebranded to Graphite Bio, Inc. in August 2020. Founded in 2017, Graphite Bio's operations are based out of its headquarters in South San Francisco, California.
Aksjekurs
$22.26
Sist synkronisert: 2024-03-22
Handel Graphite Bio, Inc. (GRPH)
Pris GRPH pris med markedsverdi på B
Markedsverdi av Graphite Bio, Inc.(GRPH)
Markedsverdi: $553.40M
Per August 2026 har Graphite Bio, Inc. en markedsverdi på $553.40M. Dette gjør Graphite Bio, Inc. til det 12737th mest verdifulle selskapet i verden basert på markedsverdi ifølge våre data. Markedsverdi er den totale markedsverdien av et børsnotert selskaps utestående aksjer og brukes vanligvis til å måle hvor mye et selskap er verdt.
Markedsverdihistorikk for Graphite Bio, Inc. fra 2021 til 2026
GRPH sammenlignet med topp 5 mest populære stocks
| Pris på GRPH |
|
Eiendel B |
Markedsverdi for B |
Resultater |
|
|
|
|
$5.264T
|
+951,087.60%
|
|
|
|
|
$4.701T
|
+849,426.54%
|
|
|
|
|
$4.177T
|
+754,721.34%
|
|
|
|
|
$3.817T
|
+689,709.24%
|
|
|
|
|
$2.866T
|
+517,850.72%
|
